Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAF V600E

Journal of Endocrinological Investigation

Volumn 36, Issue 11, 2013, Pages 1099-1104

  Kim, S H ^a   Kang, J G ^a   Kim, C S ^a   Ihm, S H ^a   Choi, M G ^a   Yoo, H J ^a   Lee, S J ^a  

^a Hallym University   (South Korea)

Author keywords

Akt; Anaplastic thyroid carcinoma; Apigenin; BRAF; PLX4032

Indexed keywords

APIGENIN; B RAF KINASE; CASPASE 3; GLUTAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN KINASE B; S6 KINASE; VALINE; VEMURAFENIB;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CELL LINE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; ONCOGENE; ONCOGENE B RAF; ONCOGENE C MYC; PROTEIN CLEAVAGE; THYROID CARCINOMA;

ANDROSTADIENES; APIGENIN; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; HUMANS; INDOLES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; SULFONAMIDES; THYROID NEOPLASMS;

EID: 84891702829     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/9099     Document Type: Article

References (30)

1. Schlumberger M. Target therapies for radioiodine refractory advanced thyroid tumors. J Endocrinol Invest 2012, 35: 40-4.
2. Akaishi J, Sugino K, Kitagawa W, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011, 21: 1183-9.
3. Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res 2011, 17: 7511-7.
4. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005, 12: 245-62.
5. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007, 28: 742-62.
6. Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between BRAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006, 13: 455-64.
7. Shukla S, Gupta S. Apigenin: a promising molecule for cancer prevention. Pharm Res 2010, 27: 962-78.
8. Choi AY, Choi JH, Lee JY, et al. Apigenin protects HT22 murine hippocampal neuronal cells against endoplasmic reticulum stress-induced apoptosis. Neurochem Int 2010, 57: 143-52.
9. Yin F, Giuliano AE, van Herle AJ. Growth inhibitory effects of flavonoids in human thyroid cancer cell lines. Thyroid 1999, 9: 369-76.
10. Yin F, Giuliano AE, van Herle AJ. Signal pathways involved in apigenin inhibition of growth and induction of apoptosis of human anaplastic thyroid cancer cells. Anticancer Res 1999, 19: 4297-304.
11. Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008, 93: 4331-41.
12. Kim SH, Kang JG, Kim CS, et al. Apigenin induces c-Myc-mediated apoptosis in FRO anaplastic thyroid carcinoma cells. Mol Cell Endocrinol 2013, 369: 130-9.
13. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467: 596-9.
14. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364: 2507-16.
15. Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2011, 72: 779-89.
16. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008, 6: 751-9.
17. Salerno P, De Falco V, Tamburrino A, et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 2010, 95: 450-5.
18. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007, 129: 1261-74.
19. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010, 20: 697-706.
20. Liu R, Liu D, Xing M. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAFV600E inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab 2012, 97: E173-82.
21. Kim SH, Kang JG, Kim CS, et al. CCAAT/enhancer-binding protein-homologous protein sensitizes to SU5416 by modulating p21 and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells. Horm Metab Res 2013, 45: 9-14.
22. Kim SH, Kang JG, Kim CS, et al. Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells. Horm Metab Res 2013, 45: 408-14.
23. Schröder-van der Elst JP, van der Heide D, Romijn JA, Smit JWA. Differential effects of natural flavonoids on growth and iodide content in a human Na+/I- symporter-transfected follicular thyroid carcinoma cell line. Eur J Endocrinol 2004, 150: 557-64.
24. Shukla S, Gupta S. Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Free Radic Biol Med 2008, 44: 1833-45.
25. Nehs MA, Nucera C, Nagarkatti SS, et al. Late intervention with anti-BRAFV600E therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology 2012, 153: 985-94.
26. Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med 2013, 368: 684-5.
27. Chen B, Tardell C, Higgins B, Packman K, Boylan JF, Niu H. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One 2012, 7: e42598.
28. Dennis PB, Pullen N, Kozma SC, Thomas G. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol Cell Biol 1996, 16: 6242-51.
29. Sonenberg N, Gingras AC. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998, 10: 268-75.
30. Pause A, Belsham GJ, Gingras AC, et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 1994, 371: 762-7.